EE80 The Potential Clinical and Economic Benefits of a Next Generation Omicron-Containing (BA.1) Bivalent Sars-Cov-2 Booster Compared to First Generation Prototype Boosters in Germany Assuming BA.4/BA.5 Dominance
Dec 1, 2022, 00:00
10.1016/j.jval.2022.09.332
https://www.valueinhealthjournal.com/article/S1098-3015(22)02536-0/fulltext
Title :
EE80 The Potential Clinical and Economic Benefits of a Next Generation Omicron-Containing (BA.1) Bivalent Sars-Cov-2 Booster Compared to First Generation Prototype Boosters in Germany Assuming BA.4/BA.5 Dominance
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)02536-0&doi=10.1016/j.jval.2022.09.332
First page :
Section Title :
Open access? :
No
Section Order :
12137